for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Valneva confirms its growth strategy and R&D outlook

June 30 (Reuters) - VALNEVA SE:

* REITERATES THAT IT EXPECTS REVENUES TO REACH EUR 105 TO EUR 115 MILLION IN 2017 AND EBITDA OF EUR 5 TO EUR 10 MILLION

* WILL PURSUE ITS STRATEGY TO GROW REVENUES TO AROUND EUR 250 MILLION BY 2020

* EXPECTS TO ANNOUNCE PHASE I RESULTS OF ITS LYME VACCINE CANDIDATE IN H1 2018 AND ACCELERATE PROGRAM’S PROGRESSION WITH VIEW TO STARTING PHASE II IN EARLY 2018

* EXPECTS TO ANNOUNCE SOME IMPORTANT RESEARCH AND DEVELOPMENT MILESTONES IN COMING MONTHS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up